Zhi Su
Department of Integrative Pharmacology
Global Pharmaceutical Research and Development
Abbott Laboratories
100 Abbott Park Road
USA
Name/email consistency: high
- A novel secretagogue increases cardiac contractility by enhancement of L-type Ca2+ current. Su, Z., Widomski, D.L., Liu, X., Limberis, J.T., Green, J., Diaz, G., Martin, R.L., Cox, B.F., Gintant, G.A. Biochem. Pharmacol. (2010)
- Electrophysiologic characterization of a novel hERG channel activator. Su, Z., Limberis, J., Souers, A., Kym, P., Mikhail, A., Houseman, K., Diaz, G., Liu, X., Martin, R.L., Cox, B.F., Gintant, G.A. Biochem. Pharmacol. (2009)
- Functional consequences of methionine oxidation of hERG potassium channels. Su, Z., Limberis, J., Martin, R.L., Xu, R., Kolbe, K., Heinemann, S.H., Hoshi, T., Cox, B.F., Gintant, G.A. Biochem. Pharmacol. (2007)
- Block of hERG channel by ziprasidone: biophysical properties and molecular determinants. Su, Z., Chen, J., Martin, R.L., McDermott, J.S., Cox, B.F., Gopalakrishnan, M., Gintant, G.A. Biochem. Pharmacol. (2006)
- Mesoridazine: an open-channel blocker of human ether-a-go-go-related gene K+ channel. Su, Z., Martin, R., Cox, B.F., Gintant, G. J. Mol. Cell. Cardiol. (2004)